Integra LifeSciences Holdings Corp (IART.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Integra LifeSciences reaffirms FY 2014 guidance


Tuesday, 5 Aug 2014 05:59am EDT 

Integra LifeSciences Holdings Corp:Continues to expect FY 2014 revenues to be between $920 - $940 mln.Revising expectations for FY 2014 GAAP earnings per diluted share to be between $1.06 - $1.24.Maintaining FY 2014 adjusted earnings per diluted share to be between $2.88 - $3.06.FY 2014 revenue of $929 mln and EPS of $2.94 - Thomson Reuters I/B/E/S.